Treatment with cytotoxic drugs

Thyroid Cancer (Second Edition)

Volumn , Issue , 2005, Pages 171-186

  Saller, B ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954759238     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-27845-1_10     Document Type: Chapter

References (67)

1. Ahuja S, Ernst H (1987) Chemotherapy of thyroid carcinoma. J Endocrinol Invest 10:303-310
2. Ain KB (1998) Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8:715-726
3. Ain KB, Tofiq S, Taylor KD (1996) Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 81:3650-3653
4. Ain KB, Egorin MJ, DeSimone PA (2000) Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) group. Thyroid 10:587-594
5. Alexieva-Figusch J, Van Gilse HA, Treurniet RE (1977) Chemotherapy in carcinoma of the thyroid: retrospective and prospective. Ann Radiol (Paris) 20:810-813
6. Asakawa H, Kobayashi T, Komoike Y, et al. (1997) Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma. Anticancer Res 17:2757-2762
7. Asakawa H, Kobayashi T, Komoike Y, et al. (1996) Establishment of anaplastic thyroid carcinoma cell lines useful for analysis of chemosensitivity and carcinogenesis. J Clin Endocrinol Metab 81:3547-3552
8. Baba M, Kobayashi T, Oka Y, et al. (1993) Preparation of a human monoclonal antibody derived from cervical lymph nodes of a patient with anaplastic carcinoma of the thyroid. Hum Antibodies Hybridomas 4:181-185
9. Barzon L, Pacenti M, Boscaro M, Palu G (2004) Gene therapy for thyroid cancer. Expert Opin Biol Ther 4:1225-1239
10. Benker G, Reinwein D (1983) Ergebnisse der Chemotherapie des Schilddrüsenkarzinoms. Dtsch Med Wochenschr 108:403-406
11. Bernhardt B (1981) Follicular thyroid carcinoma: response to chemotherapy. Am J Med Sci 282:45-46
12. Blagosklonny MV, Giannakakou P, Wojtowicz M, et al. (1998) Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 83:2516-2522
13. Bonadonna G, Monfardini S, DeLena M, Fossate F, Bellani-Fossati F, Beretta G (1970) Phase I and preliminary phase II evaluation of adriamycin (NSC 123 127). Cancer Res 30:2572
14. Braga-Basaria M, Ringel MD (2003) Clinical review 158: Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. J Clin Endocrinol Metab 88:1947-1960
15. Broecker M, de Buhr I, Mann K, Derwahl M (1999) The resistance of undifferentiated thyroid carcinoma cells to chemotherapeutic treatment with doxorubicin, cisplatin and camptothecin is due to a diminished rate of apoptosis. J Endocrinol Invest 22 [Supp]:73
16. Bukowski RM, Brown L, Weick JK, Groppe CW, Purvis J (1983) Combination chemotherapy of metastatic thyroid cancer. Phase II study. Am J Clin Oncol 6:579-581
17. Burgess MH, Stratton Hill C (1978) Chemotherapy in the management of thyroid cancer. In: Greenfield LD (ed) Thyroid cancer. CRC Press, Palm Beach, p 233
18. Chemotherapy Committee TJSoTS (1995) Intensive chemotherapy for anaplastic thyroid carcinoma: combination of cisplatin, doxorubicin, etoposide and peplomycin with granulocyte granulocyte colony-stimulating factor support. Jpn J Clin Oncol 25:203-207
19. De Besi P, Busnardo B, Toso S, et al. (1991) Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest 14:475-480
20. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Over-moyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408-3416
21. Droz JP, Schlumberger M, Rougier P, Ghosn M, Gardet P, Parmentier C (1990) Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 76:480-483
22. Dziba JM, Marcinek R, Venkataraman G, Robinson JA, Ain KB (2002) Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid 12:1063-1070
23. Ekman ET, Lundell G, Tennvall J, Wallin G (1990) Chemotherapy and multimodality treatment in thyroid carcinoma. Otolaryngol Clin North Am 23:523-527
24. Farid NR, Shi Y, Zou M (1994) Molecular basis of thyroid cancer. Endocr Rev 15:202-232
25. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M (1999) Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 141:443-457
26. Fortune JM, Osheroff N (2000) Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 64:221-253
27. Gottlieb JA, Hill CS Jr, (1974) Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med 290:193-197
28. Gottlieb JA, Hill CS Jr, Ibanez ML, Clark RL (1972) Chemotherapy of thyroid cancer. An evaluation of experience with 37 patients. Cancer 30:848-853
29. Gottlieb JA, Stratton Hill C (1975) Adriamycin (NSC 123 127) therapy in thyroid carcinoma. Cancer Chemother Rep 6:283-296
30. Grunwald F, Pakos E, Bender H, et al. (1998) Redifferentiation therapy with retinoic acid in follicular thyroid cancer. J Nucl Med 39:1555-1558
31. Hall AG (1999) Glutathione and the regulation of cell death. Adv Exp Med Biol 457:199-203
32. Hama Y, Shimizu T, Hosaka S, Sugenoya A, Usuda N (1997) Therapeutic efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) for human anaplastic thyroid carcinoma in nude mice. Exp Toxicol Pathol 49:239-247
33. Harada T, Nishikawa Y, Suzuki T, Ito K, Baba S (1971) Bleomycin treatment for cancer of the thyroid. Am J Surg 122:53-57
34. Hoskin PJ, Harmer C (1987) Chemotherapy for thyroid cancer. Radiother Oncol 10:187-194
35. Jereb B, Stjernsward J, Lowhagen T (1975) Anaplastic giant-cell carcinoma of the thyroid. A study of treatment and prognosis. Cancer 35:1293-1295
36. Kavallaris M (1997) The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance. Anticancer Drugs 8:17-25
37. Kim JH, Leeper RD (1987) Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 60:2372-2375
38. Kobayashi T, Asakawa H, Umeshita K, et al. (1996) Treatment of 37 patients with anaplas-tic carcinoma of the thyroid. Head Neck 18:36-41
39. Kober F, Heiss A, Keminger K, Depisch D (1990) Chemotherapie hochmaligner Schild-drüsentumore. Wien Klin Wochenschr 102:274-276
40. Kotchetkov R, Groschel B, Gmeiner WH, Krivtchik AA, Trump E, Bitoova M, Cinatl J, Ko-rnhuber B, Cinatl J (2000) Antineoplastic activity of a novel multimeric gemcitabine-mo-nophosphate prodrug against thyroid cancer cells in vitro. Anticancer Res 20:2915-2922
41. Leaf AN, Wolf BC, Kirkwood JM, Haselow RE (2000) Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385). Med Oncol 17:47-51
42. Morris JC, Kim CK, Padilla ML, Mechanick JI (1997) Conversion of non-iodine-concentrating differentiated thyroid carcinoma metastases into iodine-concentrating foci after anticancer chemotherapy. Thyroid 7:63-66
43. Podtcheko A, Ohtsuru A, Tsuda S, Namba H, Saenko V, Nakashima M, Mitsutake N, Kanda S, Kurebayashi J, Yamashita S (2003) The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 88:1889-1896
44. Poster DS, Bruno S, Penta J, Pina K, Catane R (1981) Current status of chemotherapy in the treatment of advanced carcinoma of the thyroid gland. Cancer Clin Trials 4:301-307
45. Ringel MD, Greenberg M, Chen X, Hayre N, Suzuki K, Priebat D, Saji M, Burman KD (2000) Cytotoxic activity of 2', 2'-difluorodeoxycytidine (gemcitabine) in poorly differentiated thyroid carcinoma cells. Thyroid 10:865-869
46. Sadani GR, Nadkarni GD (1996) Role of tissue antioxidant defence in thyroid cancers. Cancer Lett 109:231-235
47. Samonigg H, Hossfeld DK, Spehn J, Fill H, Leb G (1988) Aclarubicin in advanced thyroid cancer: a phase II study. Eur J Cancer Clin Oncol 24:1271-1275
48. Santini F, Bottici V, Elisei R, Montanelli L, Mazzeo S, Basolo F, Pinchera A, Pacini F (20 02) Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab 87:4160-4165
49. Satake S, Sugawara I, Watanabe M, Takami H (1997) Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines. Cancer Lett 116:33-39
50. Sauerwein W, Reiners C, Lederbogen S (1996) Kombinierte Strahlen-Chemotherapie beim anaplastischen Schilddrüsenkarzinom. In: Usadel K-H, Weinheimer B (eds) Schilddrüse 1995. de Gruyter, Berlin, pp 401-408
51. Scherubl H, Raue F, Ziegler R (1990) Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 116:21-23
52. Schlumberger M, Parmentier C, Delisle MJ, Couette JE, Droz JP, Sarrazin D (1991) Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 67:564-566
53. Serrano M, Monroy C, Rodriguez-Garcia JL, Pais JR, Fernandez-Garrido M (1994) Trata-miento combinado del carcinoma anaplásico de tiroides. Ann Med Interna 11:288-290
54. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155-2160
55. Simon D, Korber C, Krausch M, Segering J, Groth P, Gorges R, Grunwald F, Muller-Gart-ner HW, Schmutzler C, Kohrle J, Roher HD, Reiners C (2002) Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 29:775-782
56. Sokal M, Harmer CL (1978) Chemotherapy for anaplastic carcinoma of the thyroid. Clin Oncol 4:3-10
57. Sugawara I, Arai T, Yamashita T, Yoshida A, Masunaga A, Itoyama S (1994) Expression of multidrug resistance-associated protein (MRP) in anaplastic carcinoma of the thyroid. Cancer Lett 82:185-188
58. Sugawara I, Masunaga A, Itoyama S, Sumizawa T, Akiyama S, Yamashita T (1995) Expression of multidrug resistance-associated protein (MRP) in thyroid cancers. Cancer Lett 95:135-138
59. Sweeney PJ, Haraf DJ, Recant W, Kaplan EL, Vokes EE (1996) Anaplastic carcinoma of the thyroid. Ann Oncol 7:739-744
60. Tallroth E, Wallin G, Lundell G, Lowhagen T, Einhorn J (1987) Multimodality treatment in anaplastic giant cell thyroid carcinoma. Cancer 60:1428-1431
61. Tennvall J, Lundell G, Hallquist A, Wahlberg P, Wallin G, Tibblin S (1994) Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group. Cancer 74:1348-1354
62. Werner B, Abele J, Alveryd A, et al. (1984) Multimodal therapy in anaplastic giant cell thyroid carcinoma. World J Surg 8:64-70
63. Williams SD, Birch R, Einhorn LH (1986) Phase II evaluation of doxorubicin plus cispla-tin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 70:405-407
64. Yamashita T, Watanabe M, Onodera M, et al. (1994) Multidrug resistance gene and P-glycoprotein expression in anaplastic carcinoma of the thyroid. Cancer Detect Prev 18:407-413
65. Ye C, Feng C, Wang S, Liu X, Lin Y, Li M (2002) Antiangiogenic and antitumor effects of endostatin on follicular thyroid carcinoma. Endocrinology 143:3522-3528
66. Yeung SC, Xu G, Pan J, Christgen M, Bamiagis A (2000) Manumycin enhances the cyto-toxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res 60:650-656
67. Zlock DW, Greenspan FS, Clark OH, Higgins CB (1994) Octreotide therapy in advanced thyroid cancer. Thyroid 4:427-431